Home Investment Portfolio Receptor-OncoTek University of Toronto (Receptor-OncoTek) Innovation Type: Therapeutics Cancer Type: Other Funding Stage: Proof of Concept Fund: Compass Rose Preclinical development of PoLi-PTX, Intraperitoneal Ovarian Cancer Therapy Related news There are currently no news items related to this portfolio company. CONNECT WITH FACIT Learn more about how we are driving made-in-Ontario oncology innovations reach the market. Name: Email: Message: Topic: GeneralFundingInvesting
